Dr Jörg Schüttrumpf

R&D

Dr Jörg Schüttrumpf, Chief Scientific Innovation Officer of Grifols, discusses advancing immunoglobulin (or IG) treatment for immune disorders.

News

New NICE guidance means that around 90 UK women with cervical cancer should be eligible for treatment with Regeneron's Libtayo each year.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.